5-acetamino-6-nitro-indane | 55491-36-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-acetamino-6-nitro-indane
• 英文别名: N-(6-nitro-2,3-dihydro-1H-inden-5-yl)acetamide；5-nitro-6-acetamido-2,3-dihydroindene；N-(6-Nitro-5-indanyl)-acetamid；5-acetamido-6-nitroindan；5-Acetamido-6-nitro-indan；N-(6-nitro-indan-5-yl)-acetamide
• CAS: 55491-36-6
• 化学式: C₁₁H₁₂N₂O₃
• 分子量: 220.228
• InChiKey: HXPPAQKBNKPAMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-acetamino-6-nitro-indane 在 盐酸 、 硫酸 、 氢溴酸 、 potassium carbonate 、 溶剂黄146 、 sodium bromide 、 copper(l) chloride 、 copper(I) bromide 、 sodium nitrite 作用下， 以 吡啶 为溶剂， 反应 4.5h， 生成 5-(4-chlorophenoxy)-6-nitroindan
  参考文献：
  名称：

  Schroder; Lehmann; Rufer, European Journal of Medicinal Chemistry, 1982, vol. 17, # 1, p. 35 - 42

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-亚甲基二氧基乙酰苯胺 以 溶剂黄146 为溶剂， 生成 5-acetamino-6-nitro-indane
  参考文献：
  名称：

  Imidazole derivatives

  摘要：

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  公开号：

  US04435406A1

文献信息

• [EN] SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS<br/>[FR] ACIDES AMINO PHENYLACETIQUES SUBSTITUES, DERIVES DE CEUX-CI, PROCEDE POUR LES PREPARER ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE CYCLOOXYGENASE 2 (COX-2)
  申请人：NOVARTIS AG

  公开号：WO2004048314A1

  公开（公告）日：2004-06-10

  Compounds of formula (I) wherein R is hydrogen, lower alkyl, (C3-C8)cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted β-naphthyl, bicyclic heterocyclic aryl, (C3-C6)cycloalkylmonocyclic carbocyclic aryl, or (C5 or C6)cycloalkane fused-monocyclic carbocyclic aryl; pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.

  式(I)中R为氢、较低的烷基、(C3-C8)环烷基、羟基、卤素、较低的烷氧基、三氟甲氧基、三氟甲基或氰基；A为联苯、可选择地取代的β-萘基、双环杂环芳基、(C3-C6)环烷基单环碳环芳基，或(C5或C6)环烷烃融合的单环碳环芳基；其药学上可接受的盐，以及其药学上可接受的酯；用于治疗COX-2依赖性疾病。
• Structure−Activity Relationships of Alkyl- and Alkoxy-Substituted 1,4-Dihydroquinoxaline-2,3-diones:  Potent and Systemically Active Antagonists for the Glycine Site of the NMDA Receptor
  作者：Sui Xiong Cai、Sunil M. Kher、Zhang-Lin Zhou、Victor Ilyin、Stephen A. Espitia、Minhtam Tran、Jon E. Hawkinson、Richard M. Woodward、Eckard Weber、John F. W. Keana

  DOI：10.1021/jm960654b

  日期：1997.2.1

  alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones (QXs), prepared as a continuation of our structure-activity relationship (SAR) study of QXs as antagonists for the glycine site of the N-methyl-D-aspartate (NMDA) receptor. The in vitro potency of these antagonists was determined by displacement of the glycine site radioligand [3H]-5,7-dichlorokynurenic acid ([3H]DCKA) in rat brain cortical membranes.

  我们报告了一系列烷基和烷氧基取代的1,4-二氢喹喔啉-2,3-二酮（QXs），作为我们对QXs作为甘氨酸位点拮抗剂的结构-活性关系（SAR）研究的延续而编写N-甲基-D-天冬氨酸（NMDA）受体。这些拮抗剂的体外药效是通过在大鼠大脑皮膜中置换甘氨酸位点放射性配体[3H] -5,7-二氯基尿酸（[3H] DCKA）来确定的。通常，甲基可以很好地取代6位的氯或溴，烷氧基取代的QX的效能比烷基或卤素取代的QX低。乙基取代的QX通常不如甲基取代的QX强，特别是在5,6,7-三取代的QX的6位上。环系统在6,7位融合的结果导致QX的效能低下。几种甲基取代的QXs是有效的甘氨酸位点拮抗剂，在小鼠的最大电击（MES）测试中具有令人惊讶的高体内活性。其中，7-氯-6-甲基-5-硝基QX（14g）（IC50 = 5 nM）和7-溴-6-甲基-5-硝基QX（14f）（IC50 = 9 nM）至6,7-二氯-5-硝基QX（2）（ACEA
• Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
  申请人：State of Oregon, acting by and through the Oregon State Board of Higher

  公开号：US05631373A1

  公开（公告）日：1997-05-20

  Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.

  治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术有关的神经元丧失的方法，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病和唐氏综合征在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、抽搐和诱导麻醉的方法是通过给需要这种治疗的动物投予烷基或偶氮取代的1,4-二氢喹喔啉-2,3-二酮或其药学上可接受的盐来实现，这些物质对甘氨酸受体具有高结合能力。
• Substituted arylamino -1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators
  申请人：Chen Huanming

  公开号：US20080146661A1

  公开（公告）日：2008-06-19

  This invention provides compounds of formula I where Ar 1 is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR 3 R 4 group is situated ortho to the NHC(═X) group; n=1 or 2; X═O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.

  这项发明提供了式I的化合物，其中Ar1是一个5到10个成员的单环或双环芳香基团，可选地取代；其中-NR3R4基团位于NHC(═X)基团的邻位；n=1或2；X=O或S；Y为O或S；q=1或0。该发明还提供了包括式I的化合物和/或其盐、酯和前药的药物组合物。这些化合物调节钾通道的激活和失活。这些化合物可用于治疗和预防受钾离子通道调节影响的疾病和紊乱，如癫痫等疾病。
• Receptor-based design of novel dihydrofolate reductase inhibitors: benzimidazole and indole derivatives
  作者：Kwasi A. Ohemeng、Barbara Roth

  DOI：10.1021/jm00108a022

  日期：1991.4

  Although many thousands of inhibitors of the enzyme dihydrofolate reductase (DHFR) have been synthesized, all of the very active compounds have been 2,4-diaminopyrimidines or very close analogues. This paper describes 2,4-diamino-6-benzylbenzimidazole (3b) and the corresponding indole (4), as well as more complex tri- and tetracyclic derivatives (5 and 6). These were designed on the basis of molecular

  尽管已经合成了数千种二氢叶酸还原酶（DHFR）抑制剂，但是所有非常有活性的化合物都是2,4-二氨基嘧啶或非常接近的类似物。本文介绍了2,4-二氨基-6-苄基苯并咪唑（3b）和相应的吲哚（4），以及更复杂的三环和四环衍生物（5和6）。这些是根据对大肠杆菌DHFR的已知X射线结构进行分子建模而设计的，目的是确定是否可以通过将一个氨基取代基置于5元含氮环中来彻底改变二氨基构型，第二个在稠环的邻位，并且仍然显着抑制DHFR。尽管电子角和键角与2,4-二氨基嘧啶的电子角和键角大不相同，pKa值在适当的范围内，并且氢键的距离看来是相当合理的。活性最高的化合物4非常不稳定，仅在10（-4）M范围内具有活性。通过建模研究，二氢茚并咪唑衍生物（如6）对酶显示出很好的拟合性，但活性较低。由于所制得的最具活性的化合物作为细菌DHFR的抑制剂比未取代的5-苄基-2,4-二氨基嘧啶弱2个数量级，因此我们得出这样的环